← Back to Screener
PureTech Health plc American Depositary Shares (PRTC)
Price$18.36
Favorite Metrics
Price vs S&P 500 (26W)-7.68%
Price vs S&P 500 (4W)5.21%
Market Capitalization$322.29M
P/E Ratio (Annual)8.14x
All Metrics
Book Value / Share (Quarterly)$1.56
P/TBV (Annual)1.17x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-34.76%
Cash Flow / Share (Quarterly)$-0.42
Price vs S&P 500 (YTD)2.84%
Net Profit Margin (TTM)792.93%
EPS (TTM)$0.21
10-Day Avg Trading Volume0.44M
EPS Excl Extra (TTM)$0.21
Revenue Growth (5Y)-13.22%
EPS (Annual)$0.21
ROI (Annual)12.24%
Net Profit Margin (5Y Avg)-296.86%
Cash / Share (Quarterly)$1.39
P/E Basic Excl Extra (TTM)8.59x
Revenue Growth QoQ (YoY)542.71%
EPS Growth (5Y)-32.45%
P/E Normalized (Annual)8.14x
ROA (Last FY)8.88%
Revenue Growth TTM (YoY)1265.60%
EBITD / Share (TTM)$0.15
ROE (5Y Avg)-3.97%
Operating Margin (TTM)549.01%
Cash Flow / Share (Annual)$-0.56
P/B Ratio1.16x
P/B Ratio (Quarterly)1.08x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)30.64x
Net Interest Coverage (TTM)-0.15x
ROA (TTM)8.77%
EV / EBITDA (TTM)5.46x
EPS Incl Extra (Annual)$0.21
Current Ratio (Annual)9.33x
Quick Ratio (Quarterly)8.39x
3-Month Avg Trading Volume0.24M
52-Week Price Return0.00%
P/E Incl Extra (TTM)8.59x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.56
P/S Ratio (Annual)90.21x
Asset Turnover (Annual)0.01x
52-Week High$148.00
Operating Margin (5Y Avg)-1010.02%
EPS Excl Extra (Annual)$0.21
CapEx CAGR (5Y)-75.53%
Tangible BV CAGR (5Y)-9.11%
26-Week Price Return1.07%
Quick Ratio (Annual)9.23x
13-Week Price Return-2.50%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)8.49x
Enterprise Value$195.836
Revenue / Share Growth (5Y)-11.39%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-5.85%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)492.42%
Cash / Share (Annual)$1.59
3-Month Return Std Dev30.49%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)-55.29%
ROE (Last FY)12.90%
Net Interest Coverage (Annual)-0.15x
EPS Basic Excl Extra (Annual)$0.21
Receivables Turnover (TTM)2.81x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$0.21
Receivables Turnover (Annual)2.48x
ROI (TTM)12.15%
P/S Ratio (TTM)68.15x
Pretax Margin (5Y Avg)-272.73%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.73
Price vs S&P 500 (52W)-35.09%
P/E Ratio (TTM)8.59x
Year-to-Date Return6.08%
5-Day Price Return0.91%
EPS Normalized (Annual)$0.21
ROA (5Y Avg)-2.71%
Net Profit Margin (Annual)1108.33%
Month-to-Date Return22.78%
Cash Flow / Share (TTM)$-0.09
EBITD / Share (Annual)$0.02
Operating Margin (Annual)329.58%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-3.66%
P/E Excl Extra (TTM)8.59x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.21
P/TBV (Quarterly)1.08x
P/B Ratio (Annual)1.17x
Pretax Margin (TTM)546.78%
Book Value / Share (Annual)$1.73
Price vs S&P 500 (13W)-5.37%
Net Margin Growth (5Y)-23.72%
Beta1.38x
Revenue / Share (TTM)$0.03
ROE (TTM)12.82%
52-Week Low$104.80
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRTCPureTech Health plc American Depositary Shares | 68.15x | 1265.60% | — | -32.45% | $18.36 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
PureTech Health is a clinical-stage biopharmaceutical company developing medicines for inflammatory, immunological, neurological, and gastrointestinal disorders, as well as intractable cancers. Key pipeline assets include Deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis and SPT-300, an oral therapy for depressive disorder.